Trial Profile

Exploratory Phase Ib/IIa Study of Intratumourally Administered Tigilanol Tiglate to Assess Safety, Tolerability and Tumour Response in Patients with Head and Neck Squamous Cell Carcinoma

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 18 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Aug 2023 According to a QBiotics Group Limited media release, QBiotics decided to end the trial on the basis it had sufficient safety information to inform the Company's subsequent Human Clinical Phase II efficacy trial in head and neck cancer which is now open at multiple sites in Australia and the UK.
16 Aug 2023 Results presented in the QBiotics Group Limited media release
31 May 2023 According to a QBiotics Group Limited media release, details of this study will be presented at the Sachs 9th Annual Immuno-Oncology Innovation Forum and the BIO International Convention, both being held in the US through June 2023, by Richard Godfrey.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com